about
Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipientPre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndromeNedd4-2 isoforms ubiquitinate individual epithelial sodium channel subunits and reduce surface expression and function of the epithelial sodium channelBK polyoma virus infection and renal disease in non-renal solid organ transplantationThe structure of the rat amiloride-sensitive epithelial sodium channel gamma subunit gene and functional analysis of its promoterGenomic organization and the 5' flanking region of the gamma subunit of the human amiloride-sensitive epithelial sodium channelSecretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPasesLipid deprivation increases surfactant phosphatidylcholine synthesis via a sterol-sensitive regulatory element within the CTP:phosphocholine cytidylyltransferase promoterScreening of Living Kidney Donors for Genetic Diseases Using a Comprehensive Genetic Testing Strategy.Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta.Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies.Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndromeAldosterone regulates a 5' variant sgk1 transcript via a shared hormone response element in the sgk1 5' regulatory regionAlternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation.Nedd4-2 isoforms differentially associate with ENaC and regulate its activity.Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domainEarly postnephrectomy donor renal function: laparoscopic versus open procedure.Coordinated DNA methylation and gene expression changes in smoker alveolar macrophages: specific effects on VEGF receptor 1 expressionAntiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Ectodomain cleavage of FLT1 regulates receptor activation and function and is not required for its downstream intracellular cleavage.Protein kinase C regulates FLT1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonistUnrecognized acute phosphate nephropathy in a kidney donor with consequent poor allograft outcome.Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.A regulated NH2-terminal Sgk1 variant with enhanced function is expressed in the collecting duct.Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene.An evolutionarily conserved N-terminal Sgk1 variant with enhanced stability and improved function.Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate alpha-ENaC and sgk1 expression in renal collecting duct epithelia.cAMP-stimulated Na+ transport in H441 distal lung epithelial cells: role of PKA, phosphatidylinositol 3-kinase, and sgk1.AVP-induced VIT32 gene expression in collecting duct cells occurs via trans-activation of a CRE in the 5'-flanking region of the VIT32 gene.Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.Late-onset BK viral nephropathy in a kidney transplant recipient.EGF regulation of proximal tubule cell proliferation and VEGF-A secretion.Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.Has the Department of Veterans Affairs Found a Way to Avoid Racial Disparities in the Evaluation Process for Kidney Transplantation?An Unexpected Surge in Plasma BKPyV Viral Load Heralds the Development of BKPyV-Associated Metastatic Bladder Cancer in a Lung Transplant Recipient With BKPyV Nephropathy.VEGF-A SELECTIVELY INHIBITS FLT1 ECTODOMAIN SHEDDING INDEPENDENT of RECEPTOR ACTIVATION and RECEPTOR ENDOCYTOSIS.Very Early Recurrence of Anti-Phospholipase A2 Receptor-Positive Membranous Nephropathy After Transplantation
P50
Q24601710-6CA24433-51C6-4700-B9D8-53C0C98D15CFQ24622189-B1C516AD-D0F8-4481-A730-398205FBCAC3Q24657768-75D8B2E7-0538-42A8-B3F5-742B0BC1ECFCQ26764877-DD02F4F7-C869-4563-A8A4-9C2CB03AC07DQ28138590-16D4B388-88B9-4942-A65C-35B33A1B58EEQ28291042-BC4970FF-6DFD-4E07-A2C1-87DCBE2B0CB0Q28483381-1EBE3E3F-E786-4069-838C-0193691EB786Q28506362-AC5B2A1A-0687-426B-A6F9-1EEB3318669CQ30362814-6F56DC91-8398-44D2-B570-8578D90244D5Q33290156-6A8DBFC5-D40E-45EE-92F1-248D7BB044C6Q33404622-9B816060-CA6F-4295-B241-22F7CF588ECEQ33410276-DFDF2CD5-21AF-4CE8-B2DD-750D56A23C49Q33425245-6FE154E9-F1D4-439E-AC67-1673ADB8D863Q33427917-9F33179E-2907-46BF-B4F4-B010E7E4FA3EQ33567485-0B4AE5B1-DD8C-4868-AEB9-22D08FBE8904Q34080032-FC6888DE-4CFA-42E9-9C2A-F4AFEA95ED26Q34409388-948BAC99-18BE-4A64-B1BD-A7EA55906A32Q35178348-53EF00E5-78E8-4E3A-96E3-4CED07FE1BD3Q35410651-81CDD4F3-38D4-4167-A25F-809B58D3490DQ36064742-D4862BFC-47B7-460B-A6C4-95E80BF3F8BFQ36188916-FA96BD3B-9D1B-4773-8A33-81BD315805F3Q36475780-D5997280-84D0-400E-A454-76237A1F1934Q36932603-2046D029-267A-4ECA-AC2F-F29BD312D772Q37230805-415B6444-7330-4FAC-8E7F-1C2A460D7FD0Q37516508-4370643C-548E-4E53-89D4-EFF694200EFEQ38369621-0FBB7987-678D-4419-85D9-D9A70ACC2884Q39266441-820F355A-C296-4A80-BA5A-31194B12A40FQ39524763-643FC5CA-2FC1-4F97-ADE1-4BFF22A83C8DQ39946395-5F2E5848-45E5-4FAB-AC52-DFA2481445A8Q40367897-F95BA83B-9670-4A22-83F5-A10B8EEFEE24Q40543273-41837221-9A03-4510-BE1D-EC994A4B2269Q40556590-A18B4906-B5F9-4142-99F5-3F351DCD286AQ41548443-04775507-5F5D-42D0-BCAB-065D2F6EEFDDQ41730994-D042DFB1-7A9A-424D-BD26-CA30C98FABA1Q42093775-515AB41F-53C6-4E5C-868A-9FCE8C1C30F5Q45162912-18461D5D-8889-477C-8482-2E8C607B2D4BQ45327363-344929D1-31A0-498F-9FF7-BEADE5CB545BQ47855516-E58D61BF-F64C-4DFD-9393-731325605FE5Q52714708-E276B1D1-87F1-4CD3-9A83-5B13E3642498Q57193559-9FA52B60-CA69-42F7-8AF0-FE148FE23DA6
P50
description
forsker
@nb
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
C. Thomas
@ast
C. Thomas
@nl
Christie Thomas
@en
Christie Thomas
@es
Christie Thomas
@nb
type
label
C. Thomas
@ast
C. Thomas
@nl
Christie Thomas
@en
Christie Thomas
@es
Christie Thomas
@nb
altLabel
C. Thomas
@en
prefLabel
C. Thomas
@ast
C. Thomas
@nl
Christie Thomas
@en
Christie Thomas
@es
Christie Thomas
@nb
P106
P1153
7404414314
P31
P496
0000-0002-5989-9685